2022 ASCO Genitourinary Cancers Symposium
Thought leaders Daniel P. Petrylak, MD; Benjamin H. Lowentritt, MD; Alan H. Bryce, MD; and Tanya Dorff, MD, joined CancerNetwork® following the 2022 Genitourinary Cancers Symposium to discuss highlights of the meeting in a game show–style production.
EP. 1: 2-Minute Drill: Experts Discuss 2022 Genitourinary Cancers Symposium
February 24th 2022Following 2022 ASCO GU, Daniel P. Petrylak, MD; Benjamin H. Lowentritt, MD; Alan H. Bryce, MD; and Tanya Dorff, MD, engage in a rapid-fire question-and-answer 2-Minute Drill program, hosted by CancerNetwork®. Topics include most surprising new data, what needs follow-up, and shameless plug.
EP. 2: 2022 Genitourinary Cancers Symposium 2-Minute Drill: Experts Review Most Impactful Data
April 20th 2022Thought leaders Daniel P. Petrylak, MD; Benjamin H. Lowentritt, MD; Alan H. Bryce, MD; and Tanya Dorff, MD, joined CancerNetwork® following the 2022 Genitourinary Cancers Symposium to discuss highlights of the meeting in a game show–style production.
EP. 3: Tislelizumab Yields QOL Benefit Over Sorafenib in First-Line Hepatocellular Carcinoma
January 21st 2023Patients with unresectable hepatocellular carcinoma experienced an improvement in several health-related quality of life measures following treatment with first-line tislelizumab compared with sorafenib.
